You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Acute coronary syndromes

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

  • Technology appraisal guidance
  • Reference number: TA335
  • Published:  25 March 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document
23 January 2015
(420.5 Kb 2 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 19 January 2015

Back to top